Research Article
Analysis of the Preventive Action of Rivaroxaban against Lower Extremity Deep Venous Thrombosis in Patients after Laparoscopic Radical Gastrectomy

Qinhui Dong,1 Xiayin Zhu,2 Yafen Gao,1 Zhengrong Wang,1 Dexing Zheng,3 and Jian Zhu4

1Department of Medical Oncology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, 317000 Zhejiang, China
2Department of Hematology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, 317000 Zhejiang, China
3Department of Vascular Surgery, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, 317000 Zhejiang, China
4Department of Radiotherapy, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, 317000 Zhejiang, China

Correspondence should be addressed to Jian Zhu; ximen1987@126.com

Received 6 July 2022; Revised 4 August 2022; Accepted 17 August 2022; Published 10 September 2022

Academic Editor: Pan Zheng

Copyright © 2022 Qinhui Dong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Gastric carcinoma (GC) is a common lethal cancer in the world. Patients are prone to develop lower extremity deep venous thrombosis (LEDVT) after laparoscopic radical gastrectomy (LRG), which threatens their life and health. Purpose. This research is to clarify the preventive action of rivaroxaban (Riv) against LEDVT in patients undergoing LRG. Methods. A retrospective study was conducted on 70 patients with GC admitted for LRG between January 2019 and January 2022, including 40 patients (observation group) receiving Riv treatment and 30 patients (conventional group) treated with air wave pressure therapy apparatus. Quality of life, coagulation function, LEDVT formation, and complications were compared between groups. Results. The observation group had better recovery of life quality than the control group, along with more effective inhibition of coagulation disorders, less DVT formation, and fewer complications. Conclusions. Compared with air wave pressure therapy apparatus, Riv has better preventive action against LEDVT in GC patients after LRG.

1. Introduction

As far as the influence of gastric carcinoma (GC) on the global population is concerned, it ranks fifth in prevalence among cancers and third in cancer-related mortality [1, 2]. Various factors, including smoking, drinking, Helicobacter pylori infection, and high salt, oil, and sugar food intake, will increase the risk of GC [3–5]. Clinically, open surgery is the major approach to treat gastric adenocarcinoma, but it is prone to cause greater harm to patients [6]. In recent years, laparoscopic surgery, a procedure less invasive with milder postoperative pain and faster recovery than open surgery, has become increasingly common [7]. However, the complexity of laparoscopic surgery for GC, improper operation of medical staff during surgery, and patient insufficient compliance can easily lead to accidents, so how to prevent all kinds of complications after surgery is critical [8, 9].

Venous thrombosis of the lower extremities is the most common adverse event after laparoscopic treatment [10]. DVT occurs when a blood clot forms in the vein of the leg. The thrombus can even rupture and travel to the lungs, resulting in potentially severe blood flow obstruction (pulmonary embolism or PE) or even death [11]. In the lower extremities, the primary route of venous blood flow
is the deep vein rather than the superficial vein. As a result, DVT causes impaired venous return of the lower extremities, resulting in limb swelling, discomfort, and gait disturbance. It is reported that nearly 2.5 to 5 percent of the population are affected by DVT at some stage in their lives [12]. Although anticoagulant therapy is widely available for the disease, more than half of patients develop postthrombotic syndrome within two years of DVT, characterized by leg pain, swelling, skin pigmentation, or venous ulcers [13, 14]. In this study, we will take rivaroxaban (Riv) as an example to explore its preventive action against lower extremity deep venous thrombosis (LEDVT) of patients after laparoscopic radical gastrectomy (LRG).

2. Methods

2.1. General Information. Seventy patients admitted and underwent LRG between January 2019 and January 2022 were selected and assigned to a control group with 30 cases and an observation group with 40 cases. The general data of the two cohorts were comparable with no statistical differences.

Patients meeting the following criteria were enrolled: (1) in accordance with the World Health Organization (WHO) tumor diagnostic criteria established in the Pathology and Genetics of Tumors of the Digestive System [15], with surgical tolerance; (2) preoperative diagnosis of LEDVT [16] by vascular ultrasonography; and (3) adults (age > 18). Patients were excluded according to the following criteria: (1) recent active bleeding, (2) blood system-related diseases or coagulopathy, (3) use of anticoagulant drugs because of other diseases, and (4) presence of LEDVT before operation.

Patients and their families were informed of this study and all signed informed consent. The Medical Ethics Committee approved the study protocol without reserves, and this study was conducted strictly following the Declaration of Helsinki.

2.2. Methods. Both groups of patients underwent LRG under general anesthesia, which was performed by the same surgical team. No hemostatics were used postoperatively. The next day after surgery, patients were instructed to ambulate to exercise their ankles, toes, knees, and other joints. In the control group, air wave pressure therapy apparatus was used to prevent LEDVT. The medical staff assisted the patient to wear the multichamber airbag leg sleeve and set the time as 30 min. The first use of the instrument followed the principle of gradually increasing the pressure, so that patients could gradually get used to it and wear it for a longer duration. The maximum tolerable pressure was determined according to patients’ feelings. The observation group was given Riv (Bayer Pharmaceuticals, approval number: H20100464, specification 10 mg/tablet) for thrombosis prophylaxis, which was administrated orally, 10 mg/time, once daily, for 10 days.

2.3. Outcome Measures

2.3.1. Postoperative Quality of Life (QoL). The postoperative life status of the two cohorts was observed and compared from the aspects of sleep status and activities of daily living (ADL). The sleep quality assessment used the Pittsburgh Sleep Quality Index (PSQI, score range: 0-21) [17], with the score in inverse proportion to the sleep quality and a score greater than 7 indicating sleep disorders. As to the ADL, it was evaluated with the activity of daily living scale [18], an instrument with a score range of 0-100. The score is negatively related to self-care ability, and a score less than 60 points means that the patient needs help in life.

2.3.2. Coagulation function. Patients’ venous blood was collected before and 10 days after surgery to measure the changes of fibrinogen (Fbg), activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT) using the LHOTSYS series automatic biochemical analyzer (approval number: Guangdong Food and Drug Supervision Machinery Z2 2012 no. 2400609, manufacturer: Shenzhen Glory Medical Co., Ltd., specification: BS-3600 T).

2.3.3. DVT Formation. DVT formation of patients, which was mainly judged by lower limb temperature, skin color, and swelling, was recorded and compared. For those with abnormalities and highly suspected DVT formation, immediate physical examination and color Doppler ultrasonography of the lower extremities were performed. Color Doppler ultrasonography diagnosis criteria for DVT are as follows: significant substantial echo in the lumen of lower limbs, no voluntary blood flow at the thrombus, and failure to deflate the patient’s veins.

2.3.4. Complication Rate. The postoperative complications of the two groups were compared. The associated indicators included nausea, vomiting, labored breathing, and chills.
Among the above indicators, PSQI and activity of daily living scale scores, coagulation function-related indicators (Fbg, APTT, PT, and TT), and incidence of DVT were the primary outcome measures, while the incidence of complications such as nausea, vomiting, labored breathing, and chills were the secondary ones.

2.4. Statistical Methods. Integrated data processing was done by SPSS 22.0 (Asia Analytics Formerly SPSS China). The
statistical method for categorical data (denoted by n (%)) was $\chi^2$; quantitative data, denoted by $X \pm S$, were analyzed by t-test or pair t-test (before and after surgery). $P < 0.05$ was the significance level for all analyses.

3. Results

3.1. General Information. The two cohorts showed no statistical difference in sex, age, body mass index (BMI), tumor node metastasis (TNM) staging, and other general data ($P > 0.05$), see Table 1 for details.

3.2. Postoperative QoL. The comparison of patients’ postoperative QoL revealed a lower PSQI score and a higher ADL score in the observation group compared with the control group, with statistical significance ($P < 0.05$, Figure 1).

3.3. Coagulation Function. Comparing patients’ coagulation function, it was found that APTT, PT, and TT were significantly higher and Fbg was lower in the observation group, versus the control group, with statistical significance ($P < 0.05$, Figure 2).

3.4. DVT Formation. The intergroup comparison of DVT formation (Table 2) showed a lower overall incidence of DVT in the observation group ($P < 0.05$).

3.5. Complication Rate. The observation group had a statistically lower complication rate than the control group, as indicated by intergroup comparison data of the incidence of complications displayed in Table 3 ($P < 0.05$).

4. Discussion

Early diagnosis and treatment of GC, a highly lethal and recurrent tumor worldwide, is crucial [19]. Laparoscopic resection has recently become a common treatment for GC, but there are still many problems caused by misoperation [20–22]. After laparoscopic surgery, the incidence of DVT increases, and postthrombotic syndrome can exert a long lasting effect on the patients’ daily life [23]. Therefore, DVT prophylaxis is necessary. This study mainly discusses the preventive action of Riv against postoperative thrombosis after LRG from two aspects: coagulation function and postoperative recovery.

In terms of coagulation function, the observation group using Riv was observed with an obviously better coagulation function than the control group. Riv, as a standard coagulation inhibitor, has an inhibiting effect on factor Xa and plays a vital part in various thromboembolic and atherothrombotic diseases [24]. Factor Xa is essential in both intrinsic and extrinsic coagulation pathways that lead to downstream thrombin activation and clot formation [25], while Riv can reversely inhibit small molecules of the free and clot-bound factor Xa. Due to this function, Riv is not only increasingly used in various vascular diseases (coronary artery diseases, peripheral artery diseases, and thrombosis prophylaxis in particular) but also applied to the treatment of nonvalvular atrial fibrillation and DVT or venous embolism [26]. Another preventive measure, air wave pressure therapy apparatus, is often used to prevent DVT due to its ability to remove thrombosis directly by compression. However, if DVT is found to exist in lower limbs upon admission, improper prevention and control of DVT with air wave pressure therapy apparatus may induce thrombosis displacement, which may lead to PE [27]. This study showed better coagulation function in the observation group due to the use of Riv that can dissolve thrombus in a molecular mechanism. Therefore, compared with the control group which only used air wave pressure therapy apparatus to break thrombus, the coagulation function of the observation group was not significantly inhibited. Take Fbg as an example, as a glycoprotein complex, Fbg is enzymatically converted into fibrin by thrombin during tissue injury, causing blood to clot and stop bleeding. A clinical study on coronavirus disease 2019 (COVID-19) found a prothrombic diathesis in critical COVID-19 patients with significantly high Fbg levels, as well as higher Fbg levels [28]. Combining the above with our findings, we can find that compared with the control group which prevented thrombosis by compression, the observation group has lower Fbg level and less DVT formation due to the effective reduction of coagulation disorders in the molecular mechanism. In the retrospective study of Zhang et al. [29], Riv was applied to patients with severe cranioencephalic injury after surgery, which also had an effective prevention effect on postoperative DVT, similar to our findings. In addition, Riv is reported to not only reduce the risk of recurrent venous thromboembolism but also have a certain preventive effect on postthrombotic syndrome [30].

When investigating patients’ QoL and complications, we found that their sleep quality and life quality were effectively improved, and the incidence of complications was reduced. Consistently, Rashki Kemmak et al. reported that Riv intervention can reduce medical costs while significantly improving the QoL of patients undergoing total knee or hip arthroplasty [31]. Also, Becattini et al. [32] pointed out that Riv reduced the adverse events of patients after laparoscopic cancer surgery by 60% compared with placebo, which was

| Table 3: Incidence of complications in two groups of patients. |
|---------------------------------------------------------------|
| **Observation group (n = 40)** | **Control group (n = 30)** | **χ²** | **P** |
| Nausea | 1 (2.50) | 0 (0.00) | — | — |
| Vomiting | 0 (0.00) | 6 (20.00) | — | — |
| Labored breathing | 0 (0.00) | 3 (10.00) | — | — |
| Chills | 1 (2.50) | 0 (0.00) | — | — |
| Incidence rate of complications | 2 (5.00) | 9 (30.00) | 8.09 | 0.005 |
consistent with our results. Thrombosis after surgery for various types of cancer has been reported in all major clinical manifestations with a significant negative impact on patient outcomes. Both proximal and distal PE can occur after DVT [33]. To make matters worse, cancer patients will have a poor prognosis and similar symptoms after thrombosis in either deep or superficial veins [34]. As a common complication after various operations, the formation of venous thromboembolism will have a certain impact on the postoperative QoL of patients [35]. Combining these, we can find that patients in the observation group treated with Riv had a faster recovery of QoL after surgery and were safer than those in the control group due to better outcomes.

The novelty of this study lies in the following: (1) The clinical effectiveness of Riv in patients after LRG was confirmed from the perspectives of PSQI and ADL scores and coagulation function-related indicators (APTT, PT, TT, and Fbg), demonstrating that it can significantly improve patients’ QoL and coagulation function. (2) From the perspective of safety, it was confirmed that Riv had a significant preventive effect on LEDVT as well as other complications in GC patients after LRG. However, there are still many deficiencies in this study. For example, we had not investigated patients’ satisfaction at discharge, which is one of the defects of this study. In future experiments, we will address it and continue to improve the treatment plan, so as to make patients more satisfied. Besides, we should detect more targeted molecules or inflammatory factors related to GC, to better monitor the recovery of patients.

5. Conclusion

Conclusively, compared with air wave pressure therapy apparatus, Riv is more effective in preventing LEDVT in patients after LRG, which is worthy of further clinical promotion.

Data Availability

The labeled datasets used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no competing interests.

Authors’ Contributions

Qinhui Dong and Xiayin Zhu contributed equally to this work and are co-first authors.

References

[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.

[2] J. Poorolajal, L. Moradi, Y. Mohammadi, Z. Cheraghi, and F. Gohari-Ensaf, “Risk factors for stomach cancer: a systematic review and meta-analysis,” Epidemiol Health, vol. 42, article e2020004, 2020.

[3] N. Putthanachat, S. Promthet, C. Hurst et al., “The XRCC1 DNA repair gene modifies the environmental risk of stomach cancer: a hospital-based matched case-control study,” BMC Cancer, vol. 17, no. 1, p. 680, 2017.

[4] D. Praud, M. Rota, C. Pelucchi et al., “Cigarette smoking and gastric cancer in the stomach cancer pooling (STOP) project,” European Journal of Cancer Prevention, vol. 27, no. 2, pp. 124–133, 2018.

[5] Y. Minami, S. Kanemura, T. Oikawa et al., “Associations of cigarette smoking and alcohol drinking with stomach cancer survival: a prospective patient cohort study in Japan,” International Journal of Cancer, vol. 143, no. 5, pp. 1072–1085, 2018.

[6] T. Son and W. J. Hyung, “Laparoscopic gastric surgery: current evidence and future perspectives,” World Journal of Gastroenterology, vol. 22, no. 2, pp. 727–735, 2016.

[7] T. K. Oh, E. Ji, and H. S. Na, “The effect of neuromuscular reversal agent on postoperative pain after laparoscopic gastric cancer surgery: comparison between the neostigmine and sugammadex,” Medicine (Baltimore), vol. 98, no. 26, article e16142, 2019.

[8] K. Chen, Y. Pan, B. Zhang, H. Maher, X. F. Wang, and X. J. Cai, “Robotic versus laparoscopic gastrectomy for gastric cancer: a systematic review and updated meta-analysis,” BMC Surgery, vol. 17, no. 1, p. 93, 2017.

[9] K. Obama, Y. M. Kim, D. R. Kang et al., “Long-term oncologic outcomes of robotic gastrectomy for gastric cancer compared with laparoscopic gastrectomy,” Gastric Cancer, vol. 21, no. 2, pp. 285–295, 2018.

[10] J. E. Ha, Y. S. Lee, H. N. Lee, and E. K. Park, “Diagnostic laparoscopy of patient with deep vein thrombosis before diagnosis of ovarian cancer: a case report,” Cancer Research and Treatment, vol. 42, no. 1, pp. 48–52, 2010.

[11] C. Broderick, L. Watson, and M. P. Armon, “Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb,” Cochrane Database of Systematic Reviews, vol. 2021, no. 1, article CD002783, 2021.

[12] K. A. Kim, S. Y. Choi, and R. Kim, “Endovascular treatment for lower extremity deep vein thrombosis: an overview,” Korean Journal of Radiology, vol. 22, no. 6, pp. 931–943, 2021.

[13] C. Kearon, E. A. Akl, J. Ornelas et al., “Antithrombotic therapy for VTE disease: chest guideline and expert panel report,” Chest, vol. 149, no. 2, pp. 315–352, 2016.

[14] T. Enden, Y. Haig, N. E. Klow et al., “The assessment of deep venous thrombosis in the lower extremity exclusion criterion,” British Journal of Radiology, vol. 22, no. 6, pp. 931–935, 2010.

[15] T. Kahles, M. L. Mono, M. R. Heldner et al., “Antithrombotic therapy for VTE disease: chest guideline and expert panel report,” Chest, vol. 149, no. 2, pp. 315–352, 2016.

[16] T. Enden, Y. Haig, N. E. Klow et al., “Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial,” Lancet, vol. 379, no. 9810, pp. 31–38, 2012.

[17] T. Kahles, M. L. Mono, M. R. Heldner et al., “Antithrombotic therapy for VTE disease: chest guideline and expert panel report,” Chest, vol. 149, no. 2, pp. 315–352, 2016.

[18] B. Tutar, F. Kantarci, O. S. Cakmak, H. Yazici, and E. Seyahi, “Assessment of deep venous thrombosis in the lower extremity in Behçet’s syndrome: MR venography versus Doppler ultrasonography,” Internal and Emergency Medicine, vol. 14, no. 5, pp. 705–711, 2019.

[19] S. H. Jeong, B. N. Jang, S. H. Kim, G. R. Kim, E. C. Park, and S. I. Jang, “Association between sedentary time and sleep
quality based on the Pittsburgh sleep quality index among South Korean adults,” *BMC Public Health*, vol. 21, no. 1, p. 2290, 2021.

[18] I. Ozsoy, B. Ozcan Kahraman, S. Acar, S. Ozalevlí, A. Akkoçu, and S. Savci, “Factors influencing activities of daily living in subjects with COPD,” *Respiratory Care*, vol. 64, no. 2, pp. 189–195, 2019.

[19] O. Sokolova and M. Naumann, “NF-κB signaling in gastric cancer,” *Toxins*, vol. 9, no. 4, p. 119, 2017.

[20] J. Yu, C. Huang, Y. Sun et al., “Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the class-01 randomized clinical trial,” *JAMA*, vol. 321, no. 20, pp. 1983–1992, 2019.

[21] C. M. Lee, J. H. Park, C. In Choi et al., “A multi-center prospective randomized controlled trial (phase III) comparing the quality of life between laparoscopy-assisted distal gastrectomy and totally laparoscopic distal gastrectomy for gastric cancer (study protocol),” *BMC Cancer*, vol. 19, no. 1, pp. 1–7, 2019.

[22] A. S. Alshahrani, G. S. Gong, and M. W. Yoo, “Comparison of long-term survival and immediate postoperative liver function after laparoscopic and open distal gastrectomy for early gastric cancer patients with liver cirrhosis,” *Gastric Cancer*, vol. 20, no. 4, pp. 744–751, 2017.

[23] X. J. Song, Z. L. Liu, R. Zeng, W. Ye, and C. W. Liu, “A meta-analysis of laparoscopic surgery versus conventional open surgery in the treatment of colorectal cancer,” *Medicine (Baltimore)*, vol. 98, no. 17, article e15347, 2019.

[24] W. Mueck, J. Stampfuss, D. Kubitza, and M. Becka, “Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban,” *Clinical Pharmacokinetics*, vol. 53, no. 1, pp. 1–16, 2014.

[25] K. P. Cabral and J. E. Ansell, “The role of factor Xa inhibitors in venous thromboembolism treatment,” *Vascular Health and Risk Management*, vol. 11, pp. 117–123, 2015.

[26] M. Ajmal, J. Friedman, Q. Sipra, and T. Lassar, “Rivaroxaban: expanded role in cardiovascular disease management—a literature review,” *Cardiovascular Therapeutics*, vol. 2021, Article ID 8886210, 9 pages, 2021.

[27] T. Mori, K. Yoshioka, and Y. Tanno, “Frequency of deep vein thrombosis at admission for acute stroke and associated factors: a cross-sectional study,” *Thrombosis Journal*, vol. 19, no. 1, p. 62, 2021.

[28] I. Eljilany and A. N. Elzouki, “D-dimer, fibrinogen, and IL-6 in COVID-19 patients with suspected venous thromboembolism: a narrative review,” *Vascular Health and Risk Management*, vol. 16, pp. 455–462, 2020.

[29] Z. L. Zhang, W. M. Liu, Y. Zhang et al., “Clinical efficacy of rivaroxaban in prevention and treatment of postoperative deep vein thrombosis for severe traumatic brain injury,” *Zhonghua Yi Xue Za Zhi*, vol. 97, no. 45, pp. 3558–3561, 2017.

[30] C. Karathanos, P. Nana, K. Sspanos et al., “Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: a systematic review and meta-analysis,” *Journal of Vascular Surgery. Venous and Lymphatic Disorders*, vol. 9, no. 6, pp. 1568–1576.e1, 2021.

[31] A. Rashki Kemmak, A. Abutorabi, and V. Alipour, “Economic evaluation of rivaroxaban versus enoxaparin for prevention of venous thromboembolism after total knee replacement and total hip replacement: a systematic review,” *Clinical Drug Investigation*, vol. 40, no. 8, pp. 715–725, 2020.